Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EBITDA (2019 - 2025)

Historic EBITDA for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$145.2 million.

  • BridgeBio Pharma's EBITDA rose 2427.69% to -$145.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$609.9 million, marking a year-over-year decrease of 1203.5%. This contributed to the annual value of -$593.0 million for FY2024, which is 237.04% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's EBITDA is -$145.2 million, which was up 2427.69% from -$134.3 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's EBITDA ranged from a high of $343000.0 in Q1 2024 and a low of -$226.0 million during Q4 2024
  • For the 5-year period, BridgeBio Pharma's EBITDA averaged around -$140.7 million, with its median value being -$146.1 million (2023).
  • In the last 5 years, BridgeBio Pharma's EBITDA soared by 10027.19% in 2024 and then tumbled by 3052915.45% in 2025.
  • Quarter analysis of 5 years shows BridgeBio Pharma's EBITDA stood at -$165.6 million in 2021, then rose by 21.97% to -$129.2 million in 2022, then tumbled by 37.28% to -$177.4 million in 2023, then fell by 27.4% to -$226.0 million in 2024, then skyrocketed by 35.76% to -$145.2 million in 2025.
  • Its last three reported values are -$145.2 million in Q3 2025, -$134.3 million for Q2 2025, and -$104.4 million during Q1 2025.